Copy Link Print Information

Concanamycin A (purity≥90%)

(Synonyms: Antibiotic X 4357B (purity≥90%); Folimycin (purity≥90%); X 4357B (purity≥90%))
28 Cited Publications
Avis client

Based on 28 publication(s) in Google Scholar

Concanamycin A (purity≥90%) (Antibiotic X 4357B) is a macrolide antibiotic, a vacuolar type H+-ATPase (V-ATPase) inhibitor. Concanamycin A (purity≥90%) is also an inhibitor of lysosomal acidification, can be used to T cell-mediated inflammation research-.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

  • CAS No.: 80890-47-7
  • Formule: C46H75NO14
  • Masse moléculaire:866.09
  • Stockage:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Concanamycin A (purity≥90%) Chemical Structure
    Concanamycin A (purity≥90%) Chemical Structure
  • Experimental Validation Results for Concanamycin A (purity≥90%)
  • Experimental Validation Results for Concanamycin A (purity≥90%)
  • Experimental Validation Results for Concanamycin A (purity≥90%)
  • Experimental Validation Results for Concanamycin A (purity≥90%)
  • Experimental Validation Results for Concanamycin A (purity≥90%)
CAS No.: 80890-47-7
Size
Prix
Stock
Quantité
Amount: USD 0.00
Please select quantity
or
or

* Veuillez sélectionner la quantité avant d'ajouter des articles.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Concanamycin A (purity≥90%):

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Trouvez votre distributeur local Your local distributor: Hycultec GmbHHycultec
  • Activité biologique
  • Chemical Information
  • Pureté et documentation
  • Références
  • Help & FAQs
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Concanamycin A (purity≥90%)

More
Customer Validation & Images
Cell Proliferation/Viability AssayCell Imaging/StainingWB
  • Cell Proliferation/Viability Assay
  • Cell Imaging/Staining
  • Cell Imaging/Staining
  • WB
  • WB

Voir tous les produits spécifiques à Isoform Antibiotic

More
Keywords
100 mg

Obtenir un devis En stock

Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Enregistrer
Sign in to MedChemExpress
Enregistrer un nouveau compte

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Concanamycin A (purity≥90%) Chemical Structure
    Concanamycin A (purity≥90%) Chemical Structure
    1/16
  • 1/16

    Concanamycin A (purity≥90%) purchased from MedChemExpress. Usage Cited in: Mol Cell. 2025 Sep 4;85(17):3333-3342.e4. [Abstract]

    Customer Validation
     Cell death analysis of GPX4 KO HT1080 cells treated with 50 μM deferoxamine (DFO), 2 μM Lip-1, 100 nM BafA1, 100 nM Concanamycin A (ConA), in the absence or presence of 2 μM Trolox as indicated.

  • 1/16

    Concanamycin A (purity≥90%) purchased from MedChemExpress. Usage Cited in: Mol Cell. 2025 Sep 4;85(17):3333-3342.e4. [Abstract]

    Customer Validation
     Concanamycin A (ConA; 100 nM; 6 h, a lysosomal inhibitor) prevented lipid peroxidation induced by cysteine deficiency in HT1080 cells.

  • 1/16

    Concanamycin A (purity≥90%) purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jul 18;16(1):6621. [Abstract]

    Customer Validation
     Pretreatment of Concanamycin A (ConcA, 1 μM; 10 min) inhibited the translocation of GFP-ATG8a to the tonoplast. ConcA was added 10 min prior to monensin treatment. Scale bar, 20 μm.

  • 1/16

    Concanamycin A (purity≥90%) purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jul 18;16(1):6621. [Abstract]

    Customer Validation
     Concanamycin A (ConcA, 1 μM; 10 min) resulted in a significant reduction in the lipidation form of ATG8 following Monensin (20 μM; 1 h) treatment in mammalian cells.

  • 1/16

    Concanamycin A (purity≥90%) purchased from MedChemExpress. Usage Cited in: Nat Nanotechnol. 2025 Feb;20(2):296-302. [Abstract]

    Customer Validation
     EGFR protein degradation evaluation in MDA-MB-231 cells after treatment with 500 nM NTZ-NPs together with CQ, Baf and Concanamycin A (ConA, 10 nM) for 24 h. Note that for the inhibitors, solvent dimethylsulfoxide (DMSO) represents the control group.

  • Concanamycin A (purity≥90%)